603456 九洲药业
2026/03 - 三个月
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入1,200,662-19.43%5,508,5955,160,5855,523,4185,445,105
减:营业总成本977,468-15.34%4,293,5964,227,8114,275,8354,281,454
    其中:营业成本763,953-18.08%3,478,5753,417,1693,443,4933,557,816
               财务费用7,525-269.07%(16,546)(77,849)(75,635)(86,168)
               资产减值损失(13,621)-49.93%(337,761)(218,482)(78,204)(59,326)
公允价值变动收益----------(35,222)
投资收益5,061-615.10%3,556(8,132)(19,364)2,070
    其中:对联营企业和合营企业的投资收益(994)-19.01%(5,449)(11,955)(7,756)59
营业利润219,838-29.41%924,945732,1861,175,7711,107,912
利润总额219,858-29.20%919,451730,6021,180,6421,103,822
减:所得税费用51,587-14.90%190,908123,535149,270182,848
净利润168,271-32.66%728,543607,0681,031,372920,973
减:非控股权益(3,813)1,151.62%(1,530)971(1,884)(197)
股东净利润172,084-31.22%730,073606,0961,033,256921,170

市场价值指针
每股收益 (元) *0.190-32.14%0.8200.6801.1601.110
每股派息 (元) *----0.3000.3000.5000.400
每股净资产 (元) *9.9961.76%9.8089.5369.4076.349
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容